The content is available as a PDF (367.2 KB).
editorial . 2020 Jul 15:ciaa996. doi: 10.1093/cid/ciaa996
Treatment of COVID-19 – Evidence-Based or Personalized Medicine?
Ferric C Fang
1,✉, Robert T Schooley
2
Ferric C Fang
1
Departments of Laboratory Medicine and Microbiology,
University of Washington School of Medicine, Seattle, Washington, USA
Find articles by Ferric C Fang
Robert T Schooley
2
Division of Infectious Diseases and Global Public Health, Center for Innovative Phage Applications and Therapeutics, University of California, San Diego, San Diego, California, USA
Find articles by Robert T Schooley
1
Departments of Laboratory Medicine and Microbiology,
University of Washington School of Medicine, Seattle, Washington, USA
2
Division of Infectious Diseases and Global Public Health, Center for Innovative Phage Applications and Therapeutics, University of California, San Diego, San Diego, California, USA
✉
to whom correspondence should be addressed: Tel: 206-221-6770; Fax: 206-616-1575; email: fcfang@uw.edu
Received 2020 Jul 9.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
PMCID: PMC7454443 PMID: 32667978
See "Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention" in volume 74 on page 144.
See commentary "Personalized therapy approach for hospitalized patients with COVID-19", ciaa964.
See commentary "Clinical Outcomes of Coronavirus Disease 2019 With Evidence-based Supportive Care", ciaa678.
See commentary "Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention" in volume 74 on page 144.